GlassScriptPhysician profile
Foiqa A Chaudhry
NPI 1235459694
$4,483.49
in general payments reported to CMS, 2019-2025
36 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.97 · 2021: $190 · 2022: $1,161 · 2023: $1,488 · 2024: $855 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,043.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $642.04 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $589.47 | 2020-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $582.36 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.08 | 2022-2024 | Jardiance |
| Mannkind Corporation | $208.55 | 2022-2024 | Afrezza |
| Insulet Corporation | $179.76 | 2022-2024 | Omnipod |
| Madrigal Pharmaceuticals | $161.05 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $153.95 | 2022-2024 | |
| Amgen INC. | $149.55 | 2023-2025 | Evenity, Tepezza, Prolia |
| Recordati_rare_diseases_inc. | $147.21 | 2023-2025 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $139.98 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $137.02 | 2022-2025 | Gvoke Hypopen |
| Cequr Corporation | $122.95 | 2022-2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $100.75 | 2022-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $84.86 | 2022-2024 | Unithroid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $73.07 | 2023-2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $71.89 | 2022-2025 | |
| Radius Health, INC. | $68.42 | 2023-2025 | Tymlos |
| Corcept Therapeutics | $63.12 | 2024-2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $62.31 | 2024 | Crysvita |
| Medtronic, INC. | $59.80 | 2022-2025 | Minimed 780g |
| Embecta Corp. | $39.98 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Esperion Therapeutics, INC. | $39.97 | 2021-2022 | |
| Becton, Dickinson and Company | $34.41 | 2022 | |
| Kyowa Kirin, INC. | $22.60 | 2024 | Crysvita |
| Alvogen INC | $21.52 | 2023 | Teriparatide |
| Tandem Diabetes Care, INC. | $21.22 | 2022 | |
| Horizon Therapeutics Plc | $20.00 | 2022 | |
| Avvisto Therapeutics, LLC | $17.55 | 2025 | Cycloset |
| Companion Medical, INC. | $16.65 | 2020 | |
| Amryt Pharma Holdings LTD | $16.58 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.51 | 2022 | |
| Beta Bionics, INC. | $14.10 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Currax Pharmaceuticals LLC | $13.58 | 2024 | Contrave |
| Nevro Corp. | $13.39 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foiqa Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.